Home › 6 Investing Lessons From The Valeant Pharmaceuticals Scandal
 

Keywords :   


6 Investing Lessons From The Valeant Pharmaceuticals Scandal

2016-03-30 00:44:10| Biotech - Topix.net

It's not every day that a company with a market cap of more than US$ 70 billion , and one that is favoured by a lot of savvy investors, loses 80% in nine months . But that's what has happened with investors in the Canada-based Valeant Pharmaceuticals , where a spate of scams has been discovered over the past few months - from bad M&A accounting, to wrongful income reporting, and now the company is facing a potential default.

Tags: lessons investing scandal pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Croda Beauty Launches New Ceramide Range
16.05Doves New Bond Strength Range Contains Proprietary Bio-Protein Care and Peptides
16.05Mount Sinai Awarded $6.6 Million from National Institutes of Health to Investigate Treatment ...
16.05Eastern North Pacific Tropical Weather Outlook
16.05Amherst Label adds third Domino press
16.05Atlantic Tropical Weather Outlook
16.05Simply.TV provides metadata to Drei TV Austria
16.05Backlash as Morrisons trials sale of New Zealand lamb
More »